NCT03449238View on ClinicalTrials.gov

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 15, 2018

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2030

Conditions
Metastatic Breast CancerBrain Metastases
Interventions
DRUG

Pembrolizumab

Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.

Trial Locations (3)

10065

RECRUITING

Weill Cornell Medicine, New York

11215

RECRUITING

Brooklyn Methodist Hospital - NewYork Presbyterian, New York

11355

RECRUITING

New York Presbyterian Hospital - Queens, New York

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER